REFERENCES
2. Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simões MJ, Cerri PS. Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int 2015;2015:421746.
3. Siddiqui JA, Partridge NC. Physiological bone remodeling: systemic regulation and growth factor involvement. Physiology (Bethesda) 2016;31:233-45.
6. Capulli M, Paone R, Rucci N. Osteoblast and osteocyte: games without frontiers. Arch Biochem Biophys 2014;561:3-12.
7. Wang L, You X, Zhang L, Zhang C, Zou W. Mechanical regulation of bone remodeling. Bone Res 2022;10:16.
8. Cullinane DM. The role of osteocytes in bone regulation: mineral homeostasis versus mechanoreception. J Musculoskelet Neuronal Interact 2002;2:242-4.
10. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009;125:229-34.
11. Durfee RA, Mohammed M, Luu HH. Review of osteosarcoma and current management. Rheumatol Ther 2016;3:221-43.
12. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clinicians 2022;72:7-33.
13. Kundu ZS. Classification, imaging, biopsy and staging of osteosarcoma. Indian J Orthop 2014;48:238-46.
14. Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J 2018;4:12.
15. Li S, Sun W, Wang H, Zuo D, Hua Y, Cai Z. Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal. Tumour Biol 2015;36:1329-38.
16. Fanelli M, Tavanti E, Patrizio MP, et al. Cisplatin resistance in osteosarcoma: in vitro validation of candidate DNA repair-related therapeutic targets and drugs for tailored treatments. Front Oncol 2020;10:331.
17. Tu J, Huo Z, Gingold J, Zhao R, Shen J, Lee DF. The histogenesis of ewing sarcoma. Cancer Rep Rev 2017;1:10.15761/CRR.1000111.
18. Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol 2008;30:425-30.
19. May WA, Grigoryan RS, Keshelava N, et al. Characterization and drug resistance patterns of Ewing’s sarcoma family tumor cell lines. PLoS One 2013;8:e80060.
20. Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with Ewing’s sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol 2015;39:189-95.
21. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a children’s oncology group study. J Clin Oncol 2009;27:2536-41.
22. Bailey KM. Prospective investigation of drug resistance: an approach to understanding and optimizing the clinical benefit of targeted agents in Ewing sarcoma. Oncotarget 2018;9:37270-1.
24. Quiroz-Munoz M, Izadmehr S, Arumugam D, Wong B, Kirschenbaum A, Levine AC. Mechanisms of osteoblastic bone metastasis in prostate cancer: role of prostatic acid phosphatase. J Endocr Soc 2019;3:655-64.
25. Turpin A, Duterque-Coquillaud M, Vieillard MH. Bone metastasis: current state of play. Transl Oncol 2020;13:308-20.
27. Joeckel E, Haber T, Prawitt D, et al. High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor. Mol Cancer 2014;13:42.
28. Ardura JA, Álvarez-Carrión L, Gutiérrez-Rojas I, Alonso V. Role of calcium signaling in prostate cancer progression: effects on cancer hallmarks and bone metastatic mechanisms. Cancers (Basel) 2020;12:1071.
29. Owyong M, Chou J, van den Bijgaart RJ, et al. MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy. Life Sci Alliance 2019;2:e201800226.
30. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34.
31. Rucci N, Teti A. Osteomimicry: how the seed grows in the soil. Calcif Tissue Int 2018;102:131-40.
32. Capulli M, Hristova D, Valbret Z, et al. Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry. Br J Cancer 2019;121:157-71.
33. Pape F, Vargas G, Clézardin P. The role of osteoclasts in breast cancer bone metastasis. J Bone Oncol 2016;5:93-5.
35. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
36. Kang J, La Manna F, Bonollo F, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett 2022;530:156-69.
37. Yin JJ, Mohammad KS, Käkönen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003;100:10954-9.
38. Eslami-s Z, Cortés-hernández LE, Alix-panabières C. The metastatic cascade as the basis for liquid biopsy development. Front Oncol 2020;10:1055.
39. Palmirotta R, Lovero D, Cafforio P, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol 2018;10:1758835918794630.
40. Li X, Seebacher NA, Hornicek FJ, Xiao T, Duan Z. Application of liquid biopsy in bone and soft tissue sarcomas: Present and future. Cancer Lett 2018;439:66-77.
41. Joerger M, Huober J. Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res 2012;192:197-223.
42. Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008;75:739-50.
43. Huang Q, Ouyang X. Biochemical-markers for the diagnosis of bone metastasis: a clinical review. Cancer Epidemiol 2012;36:94-8.
44. Kushlinskii NE, Babkina IV, Solov’ev YN, Trapeznikov NN. Vascular endothelium growth factor and angiogenin in the serum of patients with osteosarcoma and Ewing’s tumor. Bull Exp Biol Med 2000;130:691-3.
45. Krizkova S, Masarik M, Majzlik P, et al. Serum metallothionein in newly diagnosed patients with childhood solid tumours. Acta Biochim Pol 2010;57:561-6.
46. Markiewicz K, Zeman K, Kozar A, Gołebiowska-Wawrzyniak M. Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report. Med Wieku Rozwoj 2011:15,25-31.
47. Liu T, Ma Q, Zhang Y, et al. Self-seeding circulating tumor cells promote the proliferation and metastasis of human osteosarcoma by upregulating interleukin-8. Cell Death Dis 2019;10:575.
49. Wit S, van Dalum G, Terstappen LW. Detection of circulating tumor cells. Scientifica (Cairo) 2014;2014:819362.
50. Yang C, Xia BR, Jin WL, Lou G. Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model. Cancer Cell Int 2019;19:341.
51. Mauri G, Bonazzina E, Amatu A, et al. The evolutionary landscape of treatment for BRAFV600E mutant metastatic colorectal cancer. Cancers 2021;13:137.
52. Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012;10:85.
53. Pellegrini C, Di Nardo L, Cipolloni G, et al. Heterogeneity of BRAF, NRAS, and TERT promoter mutational status in multiple melanomas and association with MC1R genotype: findings from molecular and immunohistochemical analysis. J Mol Diagn 2018;20:110-22.
54. Rashid FA, Bhat GH, Khan MS, Tabassum S, Bhat MH. Variations in
55. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472-84.
56. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014;30:255-89.
57. Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells 2019;8:727.
58. Stevic I, Buescher G, Ricklefs FL. Monitoring therapy efficiency in cancer through extracellular vesicles. Cells 2020;9:130.
59. Green TM, Alpaugh ML, Barsky SH, Rappa G, Lorico A. Breast cancer-derived extracellular vesicles: characterization and contribution to the metastatic phenotype. Biomed Res Int 2015;2015:634865.
60. Taverna S, Giusti I, D’Ascenzo S, Pizzorno L, Dolo V. Breast cancer derived extracellular vesicles in bone metastasis induction and their clinical implications as biomarkers. Int J Mol Sci 2020;21:3573.
61. Loftus A, Cappariello A, George C, et al. Extracellular vesicles from osteotropic breast cancer cells affect bone resident cells. J Bone Miner Res 2020;35:396-412.
62. Cappariello A, Rucci N. Tumour-derived extracellular vesicles (EVs): a dangerous “Message in A Bottle” for bone. Int J Mol Sci 2019;20:4805.
63. Valencia K, Luis-Ravelo D, Bovy N, et al. miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Mol Oncol 2014;8:689-703.
64. Ucci A, Cappariello A, Ponzetti M, et al. Anti-osteoblastogenic, pro-inflammatory and pro-angiogenic effect of extracellular vesicles isolated from the human osteosarcoma cell line MNNG/HOS. Bone 2021;153:116130.
65. Lan M, Zhu XP, Cao ZY, Liu JM, Lin Q, Liu ZL. Extracellular vesicles-mediated signaling in the osteosarcoma microenvironment: Roles and potential therapeutic targets. J Bone Oncol 2018;12:101-4.
66. Perut F, Roncuzzi L, Baldini N. The emerging roles of extracellular vesicles in osteosarcoma. Front Oncol 2019;9:1342.
67. Gassmann H, Schneider K, Evdokimova V, et al. Ewing sarcoma-derived extracellular vesicles impair dendritic cell maturation and function. Cells 2021;10:2081.
68. Pachva MC, Lai H, Jia A, Rouleau M, Sorensen PH. Extracellular vesicles in reprogramming of the ewing sarcoma tumor microenvironment. Front Cell Dev Biol 2021;9:726205.
69. Bebelman MP, Janssen E, Pegtel DM, Crudden C. The forces driving cancer extracellular vesicle secretion. Neoplasia 2021;23:149-57.
70. Ludwig N, Whiteside TL, Reichert TE. Challenges in exosome isolation and analysis in health and disease. Int J Mol Sci 2019;20:4684.
71. Kim KM, Abdelmohsen K, Mustapic M, Kapogiannis D, Gorospe M. RNA in extracellular vesicles. Wiley Interdiscip Rev RNA 2017;8:e1413.
72. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017;14:531-48.
73. Incorvaia L, Castiglia M, Perez A, et al. Liquid biopsy in breast cancer. In Liquid biopsy in cancer patients Current Clinical Pathology; Cham: Humana Press; 2017. p. 77-84.
74. Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 2015;7:1034-47.
75. Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015;7:302ra133.
76. Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 2014;20:2643-50.
77. Pécuchet N, Zonta E, Didelot A, et al. Base-position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study. PLoS Med 2016;13:e1002199.
78. Jia J, Huang B, Zhuang Z, Chen S. Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis. Int J Biol Markers 2018;33:222-30.
79. Vandekerkhove G, Struss WJ, Annala M, et al. Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer. Eur Urol 2019;75:667-75.
80. Bidard F, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014;15:406-14.
81. Moussavi-Harami SF, Wisinski KB, Beebe DJ. Circulating tumor cells in metastatic breast cancer: a prognostic and predictive marker. J Patient Cent Res Rev 2014;1:85-92.
82. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 2010;21:33-9.
83. Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-44.
84. Cheng M, Liu L, Yang HS, Liu GF. Circulating tumor cells are associated with bone metastasis of lung cancer. Asian Pac J Cancer Prev 2014;15:6369-74.
85. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556-63.
86. Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-9.
87. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
88. Helo P, Cronin AM, Danila DC, et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 2009;55:765-73.
89. Bortolini Silveira A, Bidard FC, Tanguy ML, et al. Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer. NPJ Breast Cancer 2021;7:115.
90. Kodahl AR, Ehmsen S, Pallisgaard N, et al. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. Mol Oncol 2018;12:925-35.
91. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
92. Wang P, Bahreini A, Gyanchandani R, et al. Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin Cancer Res 2016;22:1130-7.
93. Rossi G, Mu Z, Rademaker AW, et al. Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res 2018;24:560-8.
94. Bhadresha KP, Patel M, Jain NK, Rawal RM. A predictive biomarker panel for bone metastases: liquid biopsy approach. J Bone Oncol 2021;29:100374.
95. Yang XR, Pi C, Yu R, et al. Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer. Clin Exp Metastasis 2021;38:109-17.
96. Wang Y, Fang YX, Dong B, et al. Discovery of extracellular vesicles derived miR-181a-5p in patient’s serum as an indicator for bone-metastatic prostate cancer. Theranostics 2021;11:878-92.
97. Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012;106:768-74.
98. Biggs CN, Siddiqui KM, Al-Zahrani AA, et al. Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry. Oncotarget 2016;7:8839-49.
99. McKiernan J, Donovan MJ, Margolis E, et al. A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10ng/mL at initial biopsy. Eur Urol 2018;74:731-8.
100. Barris DM, Weiner SB, Dubin RA, et al. Detection of circulating tumor DNA in patients with osteosarcoma. Oncotarget 2018;9:12695-704.
101. Shulman DS, Klega K, Imamovic-Tuco A, et al. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s oncology group. Br J Cancer 2018;119:615-21.
102. Shukla NN, Patel JA, Magnan H, et al. Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with
103. Hayashi M, Chu D, Meyer CF, et al. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer 2016;122:3015-23.
104. Zhang H, Gao P, Xiao X, et al. A liquid biopsy-based method for the detection and quantification of circulating tumor cells in surgical osteosarcoma patients. Int J Oncol 2017;50:1075-86.
105. Li M, Lu Y, Long Z, et al. Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma. J Bone Oncol 2019;16:100236.
106. Wu ZJ, Tan JC, Qin X, Liu B, Yuan ZC. Significance of circulating tumor cells in osteosarcoma patients treated by neoadjuvant chemotherapy and surgery. Cancer Manag Res 2018;10:3333-9.
107. Chalopin A, Tellez-Gabriel M, Brown HK, et al. Isolation of circulating tumor cells in a preclinical model of osteosarcoma: effect of chemotherapy. J Bone Oncol 2018;12:83-90.
108. Benini S, Gamberi G, Cocchi S, et al. Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients. Cancer Manag Res 2018;10:49-60.
109. Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol 2003;21:85-91.
110. Hayashi M, Zhu P, McCarty G, et al. Size-based detection of sarcoma circulating tumor cells and cell clusters. Oncotarget 2017;8:78965-77.
111. Bao Q, Gong L, Wang J, Wen J, Shen Y, Zhang W. Extracellular vesicle RNA sequencing reveals dramatic transcriptomic alterations between metastatic and primary osteosarcoma in a liquid biopsy approach. Ann Surg Oncol 2018;25:2642-51.
112. Ma W, Zhang X, Chai J, Chen P, Ren P, Gong M. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma. Tumour Biol 2014;35:12467-72.
113. Allen-rhoades W, Kurenbekova L, Satterfield L, et al. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med 2015;4:977-88.
114. Wang SN, Luo S, Liu C, et al. miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting αB-crystallin. Mol Ther 2017;25:2140-9.
115. Yang Z, Zhang Y, Zhang X, et al. Serum microRNA-221 functions as a potential diagnostic and prognostic marker for patients with osteosarcoma. Biomed Pharmacother 2015;75:153-8.
116. Wang T, Ji F, Dai Z, Xie Y, Yuan D. Increased expression of microRNA-191 as a potential serum biomarker for diagnosis and prognosis in human osteosarcoma. Cancer Biomark 2015;15:543-50.
117. Zhou S, Wang B, Hu J, et al. miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma. Tumour Biol 2016;37:9001-7.
118. Cong C, Wang W, Tian J, Gao T, Zheng W, Zhou C. Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma. Cancer Biomark 2018;21:449-54.
119. Yao ZS, Li C, Liang D, et al. Diagnostic and prognostic implications of serum miR-101 in osteosarcoma. Cancer Biomark 2018;22:127-33.
120. Cai H, Zhao H, Tang J, Wu H. Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma. J Surg Res 2015;194:505-10.
121. Nie CL, Ren WH, Ma Y, Xi JS, Han B. Circulating miR-125b as a biomarker of Ewing’s sarcoma in Chinese children. Genet Mol Res 2015;14:19049-56.
122. Samuel G, Crow J, Klein JB, et al. Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers. Oncotarget 2020;11:2995-3012.
123. Russano M, Napolitano A, Ribelli G, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res 2020;39:95.
124. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
125. Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 2015;7:313ra182.
126. O’Leary B, Hrebien S, Morden JP, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun 2018;9:896.
127. O’Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov 2018;8:1390-403.
128. Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 2016;34:2961-8.
129. Galardi F, De Luca F, Biagioni C, et al. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Res 2021;23:38.
130. Okegawa T, Itaya N, Hara H, Tambo M, Nutahara K. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. Anticancer Res 2014;34:6705-10.
131. Liu W, Zhao X, Zhang YJ, Fang GW, Xue Y. MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res 2018;46:975-83.
132. Yuan J, Chen L, Chen X, Sun W, Zhou X. Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res 2012;40:2090-7.
133. Xavier CPR, Caires HR, Barbosa MAG, Bergantim R, Guimarães JE, Vasconcelos MH. The role of extracellular vesicles in the hallmarks of cancer and drug resistance. Cells 2020;9:1141.
134. Torreggiani E, Roncuzzi L, Perut F, Zini N, Baldini N. Multimodal transfer of MDR by exosomes in human osteosarcoma. Int J Oncol 2016;49:189-96.
135. Yoshida A, Fujiwara T, Uotani K, et al. Clinical and functional significance of intracellular and extracellular microRNA-25-3p in osteosarcoma. Acta Med Okayama 2018;72:165-74.
136. Wei F, Ma C, Zhou T, et al. Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p. Mol Cancer 2017;16:132.
137. Yuwen D, Ma Y, Wang D, et al. Prognostic role of circulating exosomal miR-425-3p for the response of NSCLC to platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev 2019;28:163-73.
138. Chen WX, Wang DD, Zhu B, et al. Exosomal miR-222 from adriamycin-resistant MCF-7 breast cancer cells promote macrophages M2 polarization via PTEN/Akt to induce tumor progression. Aging (Albany NY) 2021;13:10415-30.
139. Kreger BT, Johansen ER, Cerione RA, Antonyak MA. The enrichment of survivin in exosomes from breast cancer cells treated with paclitaxel promotes cell survival and chemoresistance. Cancers (Basel) 2016;8:111.
140. Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2012;227:658-67.
141. Yang SJ, Wang DD, Li J, et al. Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer. Gene 2017;623:5-14.
142. Wang T, Ning K, Lu TX, et al. Increasing circulating exosomes-carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients. Cancer Sci 2017;108:448-54.
143. Kharaziha P, Chioureas D, Rutishauser D, et al. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget 2015;6:21740-54.
144. Pittella-Silva F, Chin YM, Chan HT, et al. Plasma or serum: which is preferable for mutation detection in liquid biopsy? Clin Chem 2020;66:946-57.
145. Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA Analysis in patients with cancer: american society of clinical oncology and college of american pathologists joint review. J Clin Oncol 2018;36:1631-41.
146. Wong KHK, Tessier SN, Miyamoto DT, et al. Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. Nat Commun 2017;8:1733.
147. Fehm TN, Meier-Stiegen F, Driemel C, et al. Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. Cytometry A 2018;93:1213-9.
148. Terai M, Mu Z, Eschelman DJ, et al. Arterial blood, rather than venous blood, is a better source for circulating melanoma cells. EBioMedicine 2015;2:1821-6.
149. Buscail E, Chiche L, Laurent C, et al. Tumor-proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells. Mol Oncol 2019;13:1811-26.
150. Heidrich I, Ačkar L, Mossahebi Mohammadi P, Pantel K. Liquid biopsies: Potential and challenges. Int J Cancer 2021;148:528-45.
151. Brennan K, Martin K, FitzGerald SP, et al. A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Sci Rep 2020;10:1039.
152. Gancitano G, Ravasio R, Dionisi M, Cortinovis D. Cost-consequence analysis of three different diagnostic strategies in the first- and second-line treatment of locally advanced or metastatic non-small-cell lung cancer. Health Econ Ther 2018;19:1.
153. Siravegna G, Bardelli A. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. Mol Oncol 2016;10:475-80.
154. Siravegna G, Bardelli A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol 2014;15:449.
155. Gutteridge A, Rathbone VM, Gibbons R, et al. Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. Cancer Med 2017;6:2194-202.
156. Catalano M, O’Driscoll L. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles 2020;9:1703244.
